Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Friday, October 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Stoke Therapeutics has announced the granting of stock options to Stephen Aschettino, effective October 15, 2026. This move is part of their compliance with Nasdaq Listing Rule 5635(c)(4). The company is known for its investigational treatment zorevunersen, aimed at Dravet syndrome, showcasing its commitment to innovative RNA medicine.

Market Sentiment Analysis

POSITIVE FACTORS

  • Stoke Therapeutics is advancing its investigational medicine zorevunersen.
  • The company is focused on restoring protein expression with RNA medicine.
  • The stock options granted indicate confidence in leadership and future growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+3%
120-day peak, hindsight
Typical move
4.4%
average across 6 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
zorevunersen
Phase 3 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com

Frequently Asked Questions

What stock options did Stoke Therapeutics grant?

Stoke Therapeutics granted stock options to purchase shares of common stock to Stephen Aschettino.

When are the stock options effective?

The stock options are effective on October 15, 2026.

What is zorevunersen developed for?

Zorevunersen is being developed as a potential treatment for Dravet syndrome.

What does Nasdaq Rule 5635(c)(4) involve?

Nasdaq Rule 5635(c)(4) involves inducement grants for stock options to attract and retain talent.

ShareAdd on Google
Tags: STOK Stoke Therapeutics zorevunersen Dravet syndrome RNA medicine
Last updated: Oct 16, 2026

Biotech snapshot

Cash runway
$354M liquidity · $19M/mo burn
~17 mo
Low dilution risk
Lead asset
zorevunersenPhase 3
Dravet Syndrome →

Catalyst track record

+3%
best trade around STOK's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for STOK.

See every catalyst's timing & PoA →